BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Golay J, Taylor RP. The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs. Antibodies (Basel) 2020;9:E58. [PMID: 33126570 DOI: 10.3390/antib9040058] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Senent Y, Tavira B, Pio R, Ajona D. The complement system as a regulator of tumor-promoting activities mediated by myeloid-derived suppressor cells. Cancer Lett 2022;549:215900. [PMID: 36087681 DOI: 10.1016/j.canlet.2022.215900] [Reference Citation Analysis]
2 Mishra AK, Ali A, Dutta S, Banday S, Malonia SK. Emerging Trends in Immunotherapy for Cancer. Diseases 2022;10:60. [DOI: 10.3390/diseases10030060] [Reference Citation Analysis]
3 Gehlert CL, Rahmati P, Boje AS, Winterberg D, Krohn S, Theocharis T, Cappuzzello E, Lux A, Nimmerjahn F, Ludwig RJ, Lustig M, Rösner T, Valerius T, Schewe DM, Kellner C, Klausz K, Peipp M. Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody. Front Immunol 2022;13:957874. [DOI: 10.3389/fimmu.2022.957874] [Reference Citation Analysis]
4 Golay J, Andrea AE, Cattaneo I. Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies. Front Immunol 2022;13:929895. [DOI: 10.3389/fimmu.2022.929895] [Reference Citation Analysis]
5 Lai PS, Usama SM, Kiew LV, Lee HB, Chung LY, Burgess K, Kue CS. Antibody-dependent cellular phagocytosis of tropomyosin receptor kinase C (TrkC) expressing cancer cells for targeted immunotherapy. Cancer Immunol Immunother 2022. [PMID: 35032175 DOI: 10.1007/s00262-022-03147-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Goldberg BS, Kaku CI, Dufloo J, Bruel T, Schwartz O, Spencer DA, Hessell AJ, Ackerman ME. Revisiting an IgG Fc Loss-of-Function Experiment: the Role of Complement in HIV Broadly Neutralizing Antibody b12 Activity. mBio 2021;12:e0174321. [PMID: 34634936 DOI: 10.1128/mBio.01743-21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Evers M, Rösner T, Dünkel A, Jansen JHM, Baumann N, Ten Broeke T, Nederend M, Eichholz K, Klausz K, Reiding K, Schewe DM, Kellner C, Peipp M, Leusen JHW, Valerius T. The selection of variable regions affects effector mechanisms of IgA antibodies against CD20. Blood Adv 2021;5:3807-20. [PMID: 34525171 DOI: 10.1182/bloodadvances.2021004598] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Nakamura A, Suzuki S, Kanasugi J, Ejiri M, Hanamura I, Ueda R, Seto M, Takami A. Synergistic Effects of Venetoclax and Daratumumab on Antibody-Dependent Cell-Mediated Natural Killer Cytotoxicity in Multiple Myeloma. Int J Mol Sci 2021;22:10761. [PMID: 34639102 DOI: 10.3390/ijms221910761] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
9 Hussain K, Cragg MS, Beers SA. Remodeling the Tumor Myeloid Landscape to Enhance Antitumor Antibody Immunotherapies. Cancers (Basel) 2021;13:4904. [PMID: 34638388 DOI: 10.3390/cancers13194904] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
10 Interdonato A, Choblet S, Sana M, Valgardsdottir R, Cribioli S, Alzani R, Roth M, Duonor-Cerutti M, Golay J. BL-01, an Fc-bearing, tetravalent CD20 × CD5 bispecific antibody, redirects multiple immune cells to kill tumors in vitro and in vivo. Cytotherapy 2021:S1465-3249(21)00749-0. [PMID: 34538717 DOI: 10.1016/j.jcyt.2021.07.012] [Reference Citation Analysis]
11 Hernández-López A, Téllez-González MA, Mondragón-Terán P, Meneses-Acosta A. Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope. Front Pharmacol 2021;12:720692. [PMID: 34489708 DOI: 10.3389/fphar.2021.720692] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
12 Taylor RP. Special Issue: The Role of Complement in Cancer Immunotherapy. Antibodies (Basel) 2021;10:29. [PMID: 34449550 DOI: 10.3390/antib10030029] [Reference Citation Analysis]
13 D S PB, Nagaraja SB, Niveditha. Monoclonal antibodies for cancerous conditions in essential medicine list: An experience from a tertiary hospital in Bengaluru, India. IJPP 2021;8:156-160. [DOI: 10.18231/j.ijpp.2021.025] [Reference Citation Analysis]
14 Tang Y, Cao Y. Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions. Pharmaceutics 2021;13:422. [PMID: 33800976 DOI: 10.3390/pharmaceutics13030422] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
15 Bednarczyk M, Medina-Montano C, Fittler FJ, Stege H, Roskamp M, Kuske M, Langer C, Vahldieck M, Montermann E, Tubbe I, Röhrig N, Dzionek A, Grabbe S, Bros M. Complement-Opsonized Nano-Carriers Are Bound by Dendritic Cells (DC) via Complement Receptor (CR)3, and by B Cell Subpopulations via CR-1/2, and Affect the Activation of DC and B-1 Cells. Int J Mol Sci 2021;22:2869. [PMID: 33799879 DOI: 10.3390/ijms22062869] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]